FDA approves Nexium for treatment of teens

Share this article:
The FDA this week cleared AstraZeneca to market its heartburn treatment Nexium to children ages 12 through 17 for the treatment of gastroesophageal reflux disease. Nexium had global sales of $4.6 billion in 2005, making it the fifth best-selling drug in the world. The drug was approved for use in adults in February 2001.
Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.